Atherosclerotic cardiovascular disease (CVD) leading to coronary heart disease is the leading cause of morbidity and mortality in the world. Nutrition is one of the key factors in the etiology of atherosclerosis. Micronutrient supplements are widely used to prevent many chronic diseases including atherosclerosis. However, scientific evidence regarding this issue is still insufficient and current data on the association of dietary micronutrients and CVD risk is contradictory. Most of the randomized studies have failed to demonstrate beneficial effects of micronutrient supplementation on markers of subclinical atherosclerosis. In this review, role of each micronutrient on subclinical atherosclerosis will be evaluated thoroughly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1381612822666151112150020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in sleep duration status and risk of high carotid intima-media thickness in children: A prospective cohort study.
Sleep Med
December 2024
Department of Epidemiology, School of Public Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University/Children Cardiovascular Research Center of Shandong University, Jinan, 250012, China. Electronic address:
Background: Short sleep duration is common in the pediatric population and is associated with an increased risk of high carotid intima-media thickness (cIMT), a marker of subclinical atherosclerosis. However, little is known regarding whether changes in sleep duration status over time can alter the risk of high cIMT in children.
Objectives: To examine the association between changes in sleep duration status and high cIMT in a cohort study of Chinese children.
Circulating Exosomal MicroRNAs and Subclinical Atherosclerosis in Obstructive Sleep Apnea.
Arch Bronconeumol
December 2024
Precision Medicine in Respiratory Diseases Group, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IISAragón), Zaragoza, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERes), Madrid, Spain; Respiratory Service, Hospital Universitario Miguel Servet, University of Zaragoza, Zaragoza, Spain.
Thyroid and cardiovascular diseases.
Turk J Med Sci
December 2024
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye.
The thyroid gland is one of the major regulator organs of hemostasis in the human body, controlling the functioning of numerous systems. Thyroid hormones exert a modulating effect on the cardiovascular system in particular, ensuring optimal functioning within the normal range. Triiodothyronine (T3), as an active form of thyroid hormone, is mainly responsible for this effect via both genomic and nongenomic mechanisms.
View Article and Find Full Text PDFThe relationship between residual insulin secretion and subclinical cardiovascular risk indices in young adults with type 1 diabetes.
J Diabetes Complications
December 2024
National and Kapodistrian University of Athens First Department of Propaedeutic and Internal Medicine, Laiko General Hospital Athens, Attiki, Greece.
Background: Patients with type 1 diabetes (DM1), even in the setting of adequate glycaemic control, have an excess risk for developing cardiovascular disease. Residual insulin secretion (RIS), measured by detectable C-peptide levels in patients with DM1, might protect against diabetes-related complications. This study aimed to examine the relationship between residual insulin secretion and prognostic markers of cardiovascular complications in patients with DM1.
View Article and Find Full Text PDFPediatrics cascade screening in inherited dyslipidemias: a lipoprotein apheresis center experience.
Endocrine
December 2024
U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa, Italy.
Familial hypercholesterolemia (FH) is less rare than one might think and, despite highly effective lipid-lowering therapies (LLT), more than half of the patients treated do not reach the lipid target indicated by the guidelines. In these patients, lipoprotein apheresis (LA) is the most effective tool to lowering apo-B containing atherogenic lipoproteins. In own center, since 1994, thanks to routinely cascade testing performed in patients who start LA, we have identified a pediatric population (30 subjects) that we analyzed retrospectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!